ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LFVN vs CRBP // GROSS PROFIT MARGIN

Lifevantage Corporation (Delaware) (NASDAQ) VS. Corbus Pharmaceuticals Holdings Inc. (NASDAQ) • 15-METRIC TALLY: LFVN 4 — CRBP 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LFVN VS. CRBP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LFVN CRBP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE 80.40% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 29.20% -35.00% +64.20 LFVN /roic <GO>
EV/EBITDA & P/E Valuation 5.5x — — TIE /valuation <GO>
Free Cash Flow Yield 14.22% — — TIE /fcf-yield <GO>
Operating Margin 5.30% — — TIE /operating-margins <GO>
Net Profit Margin 4.30% — — TIE /net-margins <GO>
Revenue Growth (YoY) 14.20% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 2.80% 0.00% +2.80 LFVN /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.98 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 8/9 2/9 +6.00 LFVN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.2 22.3 +20.90 LFVN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 6.3x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $73.9M $75.7M -$1.8M CRBP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LFVN REV CRBP REV LFVN GROSS % CRBP GROSS % LFVN FCF CRBP FCF
FY 2025 $228.5M $238.9M 80.4% — $10.5M -$64.5M
FY 2024 $200.2M $136.4M 79.3% — $10.0M -$41.8M
FY 2023 $213.4M $126.2M — — $6.8M -$36.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LFVN // BETA —
CRBP // BETA —